[go: up one dir, main page]

UY37866A - Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. - Google Patents

Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.

Info

Publication number
UY37866A
UY37866A UY0001037866A UY37866A UY37866A UY 37866 A UY37866 A UY 37866A UY 0001037866 A UY0001037866 A UY 0001037866A UY 37866 A UY37866 A UY 37866A UY 37866 A UY37866 A UY 37866A
Authority
UY
Uruguay
Prior art keywords
myc
cbp
cells
inhibit
acetyltranspherase
Prior art date
Application number
UY0001037866A
Other languages
English (en)
Inventor
Raul Medina Jesus
Xinrong Tian
L Graybill Todd
A Heerding Dirk
Hoi Hong Li William
Biju Mangatt
Cuthbert MARTYR
Raphael, (Ralph) Anthony RIVERO
Christina Dimarco
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY37866A publication Critical patent/UY37866A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nuevos compuestos derivados de bencimidazol, de acuerdo con Fórmula lb, que disminuyen la proteína MYC (c-MYC) en células y / o inhiben la histona acetiltransferasa p300 / CBP y pueden ser útiles en el tratamiento de hipertrofia cardíaca, diabetes, obesidad y enfermedad de hígado graso no alcohólico, VIH, enfermedad renal poliquística, enfermedades inflamatorias, espondilitis anquilosante, psoriasis, artritis psoriásica, artritis reumatoide, enfermedad de Crohn, esclerosis múltiple, cáncer y síndromes precancerosos, y enfermedades asociadas con la desregulación de Myc o la inhibición de la histona acetiltransferasa p300 / CBP.
UY0001037866A 2017-09-07 2018-09-05 Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. UY37866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555164P 2017-09-07 2017-09-07
US201762587004P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
UY37866A true UY37866A (es) 2019-03-29

Family

ID=63686027

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037866A UY37866A (es) 2017-09-07 2018-09-05 Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.

Country Status (3)

Country Link
TW (1) TW201922721A (es)
UY (1) UY37866A (es)
WO (1) WO2019049061A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3930838T3 (pl) * 2019-02-27 2024-12-02 Constellation Pharmaceuticals, Inc. Pochodne n-(pirydynylo)acetamidu jako inhibitory hat p300/cbp oraz sposoby ich zastosowania
CN111848626B (zh) * 2019-04-30 2021-11-30 江苏柯菲平医药股份有限公司 Trk激酶抑制剂及其用途
WO2021061823A1 (en) * 2019-09-23 2021-04-01 Boragen, Inc. Chemical compounds
CN110551147B (zh) * 2019-09-29 2021-11-26 蚌埠产品质量监督检验研究院 一种3-环丙基苯硼酸的合成方法
GB201914989D0 (en) * 2019-10-16 2019-11-27 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for TAU Aggregates
US20230338350A1 (en) * 2020-07-03 2023-10-26 Nihon Nohyaku Co., Ltd. Anticoccidial agent and method for using the same
CN112190581B (zh) * 2020-11-04 2021-12-24 徐州医科大学 吡咯烷-2-酮类化合物在制备与多发性骨髓瘤有关药物方面的应用
JPWO2022138944A1 (es) * 2020-12-25 2022-06-30
EP4349824A4 (en) * 2021-06-02 2024-10-16 Nihon Nohyaku Co., Ltd. BENZIMIDAZOLE COMPOUND OR SALT THEREOF, CANINE FILARIASIS CONTROL AGENT CONTAINING SAME AND METHOD OF USE THEREOF
CN113387934B (zh) * 2021-06-07 2023-03-07 中山大学 一种多芳基取代咪唑衍生物及其制备方法与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
HUE065675T2 (hu) 2002-07-03 2024-06-28 Ono Pharmaceutical Co PD-L1 elleni antitesteket tartalmazó immunpotenciáló készítmények
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
JP4532409B2 (ja) 2003-01-23 2010-08-25 小野薬品工業株式会社 ヒトｐｄ−１に対し特異性を有する物質
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2005121142A1 (en) 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP2982379A1 (en) 2005-07-01 2016-02-10 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
PT2376535T (pt) 2008-12-09 2017-06-23 Hoffmann La Roche Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
SMT202000195T1 (it) 2009-11-24 2020-05-08 Medimmune Ltd Agenti leganti direzionati contro b7-h1
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
UA117220C2 (uk) 2011-08-01 2018-07-10 Дженентек, Інк. Способи лікування раку з використанням антагоністів, що зв'язуються з віссю pd-1, і інгібіторів mek
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
KR102193343B1 (ko) 2012-05-15 2020-12-22 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
CN107892719B (zh) 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
US20160235716A1 (en) 2014-09-18 2016-08-18 Abbvie Inc. Spirocyclic hat inhibitors and methods for their use
WO2016197078A1 (en) * 2015-06-05 2016-12-08 Syros Pharmaceuticals, Inc. Compounds for the modulation of myc activity
CN106977443A (zh) * 2017-04-24 2017-07-25 南昌大学 一类o‑苄基取代的异羟肟酸衍生物及其制备方法和药物的用途

Also Published As

Publication number Publication date
TW201922721A (zh) 2019-06-16
WO2019049061A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
UY37866A (es) Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
IL282468A (en) 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EA202191432A1 (ru) Агонисты glp-1r и их применения
BR112022002581A2 (pt) Inibidores heterocíclicos de rip1 quinase
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
MX2017012512A (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
EP4167993A4 (en) 2-OXOIMIDAZOLIDINE-3-CARBOXAMIDES USEFUL AS NAV1.8 INHIBITORS
CL2024001474A1 (es) Compuestos derivados de heterociclos sustituidos, activadores akt3; composición farmacéutica; y uso
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
UA103327C2 (en) Substituted pyridin-2-ones and pyridazin-3-ones
CL2014002541A1 (es) Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades.
WO2019209995A3 (en) Optimized anti-tl1a antibodies
EP3815164A4 (en) ELECTROCATALYTIC COMPOSITION AND CATHODE FOR NITROGEN REDUCTION REACTION
EA201890572A1 (ru) Биофармацевтические композиции
CL2008003524A1 (es) Composicion farmaceutica que comprende al menos un inhibidor de proteina quinasa dependiente de arn de doble hebra (pkr), uso de la composicion para el tratamiento de una condicion seleccionada de cancer, anorexia, enfermedad inflamatoria, sepsis, falla cardiaca congestiva, artritis reumatoidea, enfermedad autoinmune, diabetes, fiebre reumatoidea, progenia.
BR112018075858A2 (pt) anticorpos anti-fator xi de coagulação
CY1125043T1 (el) Ενωση τριπεπτιδιο, μεθοδος παρασκευης αυτης, και εφαρμογη αυτης
CL2024000667A1 (es) Compuestos clorados de tetralina y composiciones farmacéuticas
MX2018015410A (es) Esteres de oxaborol y sus usos.
BR112018004717A2 (pt) ?composição?
EP3739677A4 (en) ANODE SLURRY COMPOSITION
BR112017000462A2 (pt) detergente para lavar louça de pastilha e métodos para a fabricação e uso do mesmo
BR112022017283A2 (pt) Cristalização de 2?-fl
PH12017500487A1 (en) Use of heterocyclic fluoroalkenyl sulfone compounds for repelling molluscs
BR112022008208A2 (pt) Compostos de d-anfetamina, composições e processos para produzir e usar os mesmos

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204